Navigation Links
Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
Date:9/13/2010

assigned a PDUFA date of October 22, 2010, for review of the application. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication, regulatory review, and potential regulatory approval and commercialization of lorcaserin; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks related to the implementation and continuation of the marketing and supply agreement with Eisai and dependence on Eisai for commercialization of lorcaserin in the United States; regulatory authorities or advisors may not find data from Arena's clinical trials and other studies sufficient for regulatory approval; the timing and ability of Arena to receive regulatory approval for its drug candidates; the ability to enter into agreements to develop or commercialize lorcaserin and other of Arena's compounds or programs; Arena's ability to commercialize lorcaserin outside of the United States with another company or independently; the timing, success and cost of the lorcaserin program and other of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and o
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
2. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
3. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
5. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
6. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
8. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
9. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
10. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... ORLEANS , May 22, 2013 ... for commercially-insured patients with Type 2 diabetes, while ... to improve health outcomes and can lead to ... presented at the International Society for Pharmacoeconomics and ... The two studies, sponsored by Valeritas, makers ...
(Date:5/22/2013)... , May 22, 2013  Generex Biotechnology Corporation ... demonstrating the superiority of the AE37 breast cancer vaccine ... ( www.antigenexpress.com ). The presentations will be made at ... Oncology (ASCO) to be held in Chicago ... The presentation entitled " Booster inoculations of ...
(Date:5/22/2013)... 22, 2013  Flagship Ventures, a leading venture ... and sustainability, today announced the appointment of ... Partner. In this role, Mr. Bancel will provide ... In addition to working closely with companies ... as President and Chief Executive Officer of Moderna ...
Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3
... Novel siRNA Structures Exhibit Stability and Activity in ... Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company focused on discovering ... Company has filed a patent application covering a ... siRNA molecule stability and,excellent penetration into the human ...
... Artificial, Intelligence-Based Drug Discovery Platform and Novel Drug Candidates to ... ... -Initial Compounds Demonstrate Promising In Vitro Activity Against, Devastating ... 27 Upstream Biosciences,Inc. (OTC Bulletin Board: UPBS) today announced it ...
Cached Medicine Technology:Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules 2Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules 3Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 2Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 3Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 4Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 5Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 6Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 7
(Date:5/22/2013)... US (PRWEB) May 22, 2013 Award ... , Read the press release here: http://bit.ly/13DkFfk ... DataSite® was named “Information Management Product/Service of the Year” ... in March at The Colony Hotel in Palm Beach, ... virtual data room (VDR) solution that optimizes ...
(Date:5/22/2013)... Utah (PRWEB) May 22, 2013 Registered Dietitian ... an article today on Tatalou.com sharing a recipe for making ... Your Own Healthy Energy Bars ,” takes a recipe modified ... few important twists. , “Every day it gets more and ... our bodies,” said Chevreau. “The size of the nutrition label ...
(Date:5/22/2013)... Pamela Isom, President and CEO of ICE Safety ... Women of Influence Award in recognition for her outstanding ... took place on Thursday, May 2 at The Fairmont, ... humbling for the 5,000 people ICE Safety Solutions certifies ... recognize the four to nine lives saved per year ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) ... children who die each year awaiting an organ donation ... increasing numbers of children are receiving donor organs. ... donors expanded to include not just patients who,ve experienced ... of death." But it,s unclear how much that ...
(Date:5/22/2013)... URBANA - A University of Illinois researcher says that ... should be to encourage more people to participate in ... , According to Craig Gundersen, SNAP, formerly known as ... net program and with some additional improvements could be ... households. Gundersen is a U of I professor of ...
Breaking Medicine News(10 mins):Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 2Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 3Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 4Health News:Alleviating hunger in the US -- researcher says, it's a SNAP 2Health News:Alleviating hunger in the US -- researcher says, it's a SNAP 3
... Expected for Western Drug Companies, According to a Report ... Resources, one of the world,s leading research and advisory ... the colorectal cancer drug market in China will ... in 2007 to $290 million in 2012. This growth ...
... Three Grand Prize Winners Will Meet Nick Jonas TARRYTOWN, N.Y., ... Jonas of the Jonas Brothers invite kids and teens with ... Contest" online for a chance to meet Nick in person. ... Care and Nick, who has type 1 diabetes and uses ...
... 13 Adam Kluger Public Relations ( www.adamklugerpr.com ) announced Monday that AKPR ... b alancecenters . ... the Brain Balance Program(R), a revolutionary new approach to help children with Autism, ... For more than ten years, Dr. Robert Melillo , author of ...
... With a Mission of Encouraging Families to Be Incredibly Active ... PARK RIDGE, Ill. April 13 Today, the nation,s egg ... providing 13,500 dyed eggs for the 2009 White ... years, the event brings together families to hunt for and ...
... DocuSyst hosts FileHold document management solution which gives customers the ability ... in software and equipment. , ... Middleton, RI (PRWEB) ... Medicine Inc. is an out patient physical therapy group that provides ...
... Priorities to Improve Health Outcomes and Reduce WasteST. LOUIS ... ESRX ), and WellPoint, Inc. (NYSE: ... a definitive agreement under which Express Scripts, one of ... America, will acquire WellPoint,s NextRx subsidiaries for $4.675 billion, ...
Cached Medicine News:Health News:Chinese Colorectal Cancer Drug Market Will More Than Double by 2012 2Health News:Nick Jonas and Bayer Diabetes Care Launch Creativity Contest to Encourage Kids With Diabetes to Express Their Simple Win 2Health News:Nick Jonas and Bayer Diabetes Care Launch Creativity Contest to Encourage Kids With Diabetes to Express Their Simple Win 3Health News:Brain Balance(TM) Centers Picks Adam Kluger Public Relations (AKPR) to Help Promote New Book and Atlanta Event to Raise Awareness About Revolutionary New Way to Treat Learning Disorders; Atlantic Recording Artist/Country Music Star Zac Brown and Dr. Rober 2Health News:America's Egg Farmers to Participate in Annual White House Easter Egg Roll Today 2Health News:America's Egg Farmers to Participate in Annual White House Easter Egg Roll Today 3Health News:Olympic Physical Therapy Clears Space and Reduces Clutter with Hosted Document Management Solution from DocuSyst 2Health News:Olympic Physical Therapy Clears Space and Reduces Clutter with Hosted Document Management Solution from DocuSyst 3Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 2Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 3Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 4Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 5Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 6Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 7Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 8
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical ...
The ImagingPlanet 80 mm surgical microscope video adapter: superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Leica surgical...
The ImagingPlanet 80 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
Medicine Products: